Brief: Innovation Pharmaceuticals opens new clinical site for novel p53 drug candidate in Phase 2 ovarian cancer trial
14/09/2017 12:30
Sept 14 (Reuters) - Innovation Pharmaceuticals Inc IPIX.PK
* Innovation Pharmaceuticals opens new clinical site for
novel p53 drug candidate in Phase 2 ovarian cancer trial
Source text for Eikon: ID:nGNXOEGDSa
Further company coverage: IPIX.PK
((Bangalore.newsroom@thomsonreuters.com; ;))
Recent news on Innovation Pharmaceuticals
See all newsBrief: Innovation Pharmaceuticals Announces New Milestone At Beamed On Track To File 510(K) Submission To FDA In Q2 2024
Brief: Innovation Pharmaceuticals Provides Update On US Patent Applications Covering Use Of Brilacidin In Inflammatory Bowel Diseases, Coronaviruses And Fungal Diseases
Brief: Innovation Pharma Reports Enrollment In Phase 2 Trial Of Brilacidin For COVID-19 Tops 70%
Brief: Innovation Pharma Surpasses 50% Enrollment In Phase 2 Clinical Trial Of Brilacidin For COVID-19
Brief: Innovation Pharma Completes Interim Safety Data Review